{
  "id": 235,
  "language": "english",
  "hallucination": "no",
  "ground_truth_source": "text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Colleagues / Co-hosts",
      "inferred_vibe": "Serious and Informative"
    },
    "dialogue_turns": [
      {
        "speaker": "Host_A",
        "text": "So, B, I was reading this article, and it really struck me how, like, despite all our talk about investing in solutions, we really have surprisingly few new TB medicines to show for, you know, decades of effort.",
        "tts_text": "So, B, I was reading this article, and it really struck me how, like, despite all our talk about investing in solutions, we really have surprisingly few new T B medicines to show for, you know, decades of effort.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "But while leaders generally agree on the need to invest in solutions, we have surprisingly few TB medicines to show for our quarter-century of effort.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Yeah, it's pretty wild when you think about it. I mean, TB, uh, it's the world's deadliest infection, right? And it's been around forever, like, theorized to be in humans for 5,000 years.",
        "tts_text": "Yeah, it's pretty wild when you think about it. I mean, T B, uh, it's the world's deadliest infection, right? And it's been around forever, like, theorized to be in humans for five thousand years.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "TB is the worlds deadliest infection, and it has been with us for a very long time. Researchers theorize that humans first acquired TB in Africa about 5,000 years ago...",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Exactly! And it's not getting better. The article says the effectiveness of treatments is actually declining because drug-resistant strains are becoming more, like, virulent. It's kinda scary.",
        "tts_text": "Exactly! And it's not getting better. The article says the effectiveness of treatments is actually declining because drug-resistant strains are becoming more, like, virulent. It's kinda scary.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "But the effectiveness of TB treatments is declining, raising concerns that drug-resistant strains are becoming more virulent.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Oh, for sure. And it's not just a medical problem, either. It, uh, it really perpetuates poverty in developing countries because families have to spend so much just managing care.",
        "tts_text": "Oh, for sure. And it's not just a medical problem, either. It, uh, it really perpetuates poverty in developing countries because families have to spend so much just managing care.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The disease perpetuates poverty in developing countries, because patients and their families must routinely spend up to half of their income buying medicines and managing care.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Right. Up to half their income! And then, with drug resistance, those expenditures don't even guarantee results. They're talking about drug-resistant TB costing the global economy something like $16.7 trillion by 2050.",
        "tts_text": "Right. Up to half their income! And then, with drug resistance, those expenditures don't even guarantee results. They're talking about drug-resistant T B costing the global economy something like sixteen point seven trillion dollars by twenty fifty.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "...patients and their families must routinely spend up to half of their income buying medicines and managing care. ... By 2050, drugresistant TB could cost the global economy as much as $16.7 trillion in medical expenses and lost wages...",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "[interrupts] Which is, like, the entire economic output of the EU! It's staggering. So, why aren't we seeing more R&D? Is it just a funding issue?",
        "tts_text": "Which is, like, the entire economic output of the E U! It's staggering. So, why aren't we seeing more R and D? Is it just a funding issue?",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "By 2050, drugresistant TB could cost the global economy as much as $16.7 trillion in medical expenses and lost wages roughly the equivalent of the European Unions entire economic output.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Pretty much. The World Health Organization says there's a $1.3 billion annual funding deficit for TB research. And, um, there's a lack of market incentives for pharmaceutical companies.",
        "tts_text": "Pretty much. The World Health Organization says there's a one point three billion dollar annual funding deficit for T B research. And, um, there's a lack of market incentives for pharmaceutical companies.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "According to the World Health Organization, the annual funding deficit for TB research and development is more than $1.3 billion, a shortfall that is exacerbated by a lack of market incentives within the pharmaceutical industry.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Yeah, I guess when two-thirds of new cases are in just eight countries, maybe the market for new drugs isn't seen as, you know, globally lucrative enough for some big players.",
        "tts_text": "Yeah, I guess when two-thirds of new cases are in just eight countries, maybe the market for new drugs isn't seen as, you know, globally lucrative enough for some big players.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Despite TBs global reach, two-thirds of new cases in 2017 occurred in just eight countries India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Which brings up that whole debate about intellectual property rights versus access, right? Like, at the UN meeting, that was a huge discussion point.",
        "tts_text": "Which brings up that whole debate about intellectual property rights versus access, right? Like, at the U N meeting, that was a huge discussion point.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The high-level meeting in September was meant to galvanize the worlds TB-eradication efforts. Unfortunately, the rare political unity in the lead-up to the discussion was overshadowed by a debate about drug makers intellectual-property rights.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Yeah, it's a real quandary. How do we ensure meds are accessible, especially for the poorest, while still, like, maintaining funding streams for pharmaceutical R&D? It's a tough balance.",
        "tts_text": "Yeah, it's a real quandary. How do we ensure meds are accessible, especially for the poorest, while still, like, maintaining funding streams for pharmaceutical R and D? It's a tough balance.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "While the declaration endorsed at the end of the UN meeting did offer a compromise, the quandary remains: how can we guarantee access to medications especially for the poorest patients while maintaining funding streams for pharmaceutical R&D?",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "But ultimately, patient needs have to come first, right? I mean, last year, an estimated 3.6 million people infected with TB couldn't even access treatment. That's, uh, that's a huge gap.",
        "tts_text": "But ultimately, patient needs have to come first, right? I mean, last year, an estimated three point six million people infected with T B couldn't even access treatment. That's, uh, that's a huge gap.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Last year, an estimated 3.6 million people infected with TB were unable to access treatment, a staggering gap in coverage that must be quickly closed.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "It really is. So, the message is clear: we need a significant increase in R&D spending and better collaboration between public and private sectors.",
        "tts_text": "It really is. So, the message is clear: we need a significant increase in R and D spending and better collaboration between public and private sectors.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Still, we cannot get over the finish line without a significant increase in research and development spending. ... The R&D burden must be shared among the public and private sectors...",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Totally. And, um, these treatments need to be universally adopted and available. Not just in a few places.",
        "tts_text": "Totally. And, um, these treatments need to be universally adopted and available. Not just in a few places.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "...and resulting treatments must be universally adopted and available.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Exactly. The longer we wait to increase R&D funding and strengthen collaboration, the higher the death toll will climb.",
        "tts_text": "Exactly. The longer we wait to increase R and D funding and strengthen collaboration, the higher the death toll will climb.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The longer we wait to increase R&D funding and strengthen collaboration on treatment, the higher TBs death toll will climb.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Yeah. With so many lives at stake, the time for talking really is over. We need action.",
        "tts_text": "Yeah. With so many lives at stake, the time for talking really is over. We need action.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "With so many lives at stake, the time for talking is over.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Agreed. We need to, uh, get these solutions out there.",
        "tts_text": "Agreed. We need to, uh, get these solutions out there.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      }
    ]
  }
}